Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal
01:12pm, Tuesday, 22'nd Apr 2025
Regeneron Pharmaceuticals, Inc. REGN on Tuesday announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture and supp
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
11:13am, Tuesday, 22'nd Apr 2025
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
11:05am, Tuesday, 22'nd Apr 2025
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron signs over $3 billion deal with contract drugmaker to boost US manufacturing
06:17am, Tuesday, 22'nd Apr 2025
Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug developer Fujifilm Diosynth to expand its U.S. manufacturing capacity.
FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 Billion
06:00am, Tuesday, 22'nd Apr 2025
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)-- #stemcells--FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced t
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
06:00am, Tuesday, 22'nd Apr 2025
New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron's biologic medicines and support high-paying jobs in the
Regeneron Announces Investor Conference Presentations
04:05pm, Monday, 21'st Apr 2025
TARRYTOWN, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
10:25am, Monday, 21'st Apr 2025
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
09:00am, Monday, 21'st Apr 2025
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
03:00pm, Friday, 18'th Apr 2025
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response lette
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
11:31am, Friday, 18'th Apr 2025
The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
11:15am, Friday, 18'th Apr 2025
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and
Regeneron: Still A Biotech Juggernaut
03:57am, Wednesday, 16'th Apr 2025
Regeneron's stock has dropped 40% due to EYLEA's IP issues, but strong financials and pipeline assets bolster optimism for long-term growth. Dupixent's robust sales growth and potential new indication
Trump Says Pharmaceutical Tariffs Coming in Near Future
02:03pm, Monday, 14'th Apr 2025
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with repo
